Description
Long-term outcomes of isatuximab in high-risk multiple myeloma
Article: Long-term outcomes of isatuximab in high-risk multiple myeloma
€3.03
Related products
-
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart -
Article: Highlights in digestive oncology
€3.03 Add to cart -
Article: Highlights in breast cancer
€3.03 Add to cart -
Article: Calendar of events
€3.03 Add to cart
